Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Moderna, Inc. - Common Stock (NQ:MRNA)

52.88 -1.47 (-2.70%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Moderna, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities
Via Investor Brand Network
InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Targets CNS Drug Delivery Opportunity as Brain Therapeutics Innovation Accelerates
Via Investor Brand Network
Topics Intellectual Property
News headline image
Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data for Its Investigational Seasonal Influenza Vaccine, mRNA-1010
Via ACCESS Newswire
News headline image
CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities
From BioMedWire
Via GlobeNewswire
News headline image
Moderna Reports First Quarter 2026 Financial Results and Provides Business Updates
Via ACCESS Newswire
News headline image
Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate
Via ACCESS Newswire
News headline image
Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting
Via ACCESS Newswire
News headline image
Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19
Via ACCESS Newswire
News headline image
Moderna to Present at Upcoming Conferences in May 2026
Via ACCESS Newswire
News headline image
Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026 AACR Annual Meeting
Via ACCESS Newswire
News headline image
Moderna to Report First Quarter 2026 Financial Results on Friday, May 1, 2026
Via ACCESS Newswire
News headline image
Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026
Via ACCESS Newswire
News headline image
Moderna Resolves Global Patent Litigation with Arbutus/Genevant
Via ACCESS Newswire
News headline image
European Medicines Agency's Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19
Via ACCESS Newswire
News headline image
Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board
From Tectonic Therapeutic
Via GlobeNewswire
News headline image
Moderna to Present at Upcoming Conferences in March 2026
Via ACCESS Newswire
News headline image
Moderna Announces the U.S. Food and Drug Administration will Initiate the Review of Its Investigational Seasonal Influenza Vaccine Submission
Via ACCESS Newswire
News headline image
Moderna Receives European Commission Marketing Authorization for COVID-19 Vaccine mNEXSPIKE
Via ACCESS Newswire
News headline image
Moderna Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Updates
Via ACCESS Newswire
News headline image
Moderna Receives Refusal-to-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, mRNA-1010
Via ACCESS Newswire
News headline image
Moderna to Enter into Long-Term Strategic Agreement with the Government of Mexico
Via ACCESS Newswire
News headline image
The $71 Billion Cancer Shift: Why The FDA Is Speeding Up
Issued on behalf of Oncolytics Biotech Inc. 
From Equity Insider
Via GlobeNewswire
News headline image
Defiance Launches MRNX: The First Daily 2X Long ETF for Moderna, Inc.
From Defiance ETFs
Via GlobeNewswire
News headline image
Dr. David Berman to Join Moderna as Chief Development Officer
Via ACCESS Newswire
News headline image
Moderna Announces Strategic Collaboration with Recordati to Globally Commercialize Investigational Propionic Acidemia Therapeutic (mRNA-3927)
Via ACCESS Newswire
News headline image
Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following
Via ACCESS Newswire
News headline image
Moderna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference
Via ACCESS Newswire
News headline image
Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine
Via ACCESS Newswire
News headline image
CEPI to Fund Pivotal Phase 3 Trial for Moderna's mRNA Pandemic Influenza Vaccine Candidate
Via ACCESS Newswire
News headline image
Moderna to Present at the 44th Annual J.P. Morgan Healthcare Conference
Via ACCESS Newswire
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.